深基质真菌性角膜炎综合治疗方案的疗效评估

doi:10.3760/cma.j.cn115909-20191218-00332

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF 7272KB HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：探讨基于角膜基质内注射伏立康唑的综合治疗方案对感染灶浸润深度达1/2角膜基质以上的深基质真菌性角膜炎的有效性和安全性。方法：回顾性临床研究。选择2013年3月至2017年7月于温州医科大学附属眼视光医院行角膜基质内注射伏立康唑治疗的深基质真菌性角膜炎患者62例（62眼）的资料进行分析。观察指标包括年龄、溃疡直径、治愈率、复发率以及并发症情况等，注射术后至少随访6个月；并根据角膜基质内注药效果将患者分为单纯角膜基质内注药有效组和单纯角膜基质内注药无效组。采用独立样本t检验及卡方检验对数据进行统计分析。结果：62例患者的溃疡直径为2.8～11.0（5.5±2.1）mm，患者发病到就诊时间为2 d～2年（44.2±98.6）d，其中6例患者主诉病史超半年，56例患者发病到就诊时间为（21.2±13.6）d；术后随访6～36（10.5±7.5）个月。单纯角膜基质内注射伏立康唑治愈42例（42眼）；1例（1眼）患者角膜基质注药有效后为提高视力行角膜移植；单纯角膜基质内注射伏立康唑无效19例（19眼），联合行结膜瓣覆盖治疗后，治愈11眼，需再行角膜移植8眼，其中2眼术后复发。该综合治疗方案治愈率为85.5%，复发率为3.2%。单纯角膜基质内注药有效组溃疡直径小于单纯角膜基质内注药无效组，差异有统计学意义（t=-2.199，P=0.032）。术中及术后随访均未见并发症。结论：角膜基质内注射伏立康唑对常规药物治疗无效的深基质真菌性角膜炎有良好的疗效并且安全性较高。而对于病灶范围广泛的患眼，单纯角膜基质内注药疗效欠佳，联合结膜瓣覆盖治疗可提高治愈率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： , 真菌性角膜炎, 伏立康唑, 角膜基质内注射, 结膜瓣覆盖

Abstract： Objective: To evaluate the efficacy and safety of a comprehensive treatment regimen based on intrastromal voriconazole injection in the treatment of deep stromal fungal keratitis in which the lesion has infiltrated more than half of the corneal stroma. Methods: This was a retrospective study. Sixty-two patients (62 eyes) with deep stromal fungal keratitis who underwent intrastromal voriconazole injection were selected at the Eye Hospital, Wenzhou Medical University from March 2013 to July 2017. Age, the diameter of the ulcer, cure rate, recurrence rate, complications, etc., were measured. All the patients were followed up for at least 6 months. Sixty-two patients were divided into an effective group (EGII) and an ineffective group (IGII) based on the effect of the pure intrastromal voriconazole injection. The data were analyzed by an independent samples t-test and Chi-square test. Results: The 62 patients had ulcer diameters ranging from 2.8 to 11.0 (5.5±2.1)mm. The time from onset to treatment for the 62 patients ranged from 2 days to 2 years (44.2±98.6)days. Six patients sought treatment more than half a year after onset, and the remaining 56 patients had an onset time of 21.2±13.6 days. All patients were followed up for 6 to 36 (10.5±7.5)months. Forty-two patients (42 eyes) were cured by pure intrastromal voriconazole injection, 1 patient (1 eye) underwent a corneal transplant to improve vision after intrastromal voriconazole injection was effective; 19 patients (19 eyes) underwent conjunctival flap coverage after the injection failed. Combined with conjunctival flap coverage, 11 eyes were cured, 8 eyes required corneal transplants, and 2 patients relapsed after corneal transplants. The cure rate of the comprehensive treatment regimen was 85.5%, and the recurrence rate was 3.2%. The EGII group had a smaller ulcer diameter than the IGII group, and the difference between the two groups was statistically significant (t=-2.199, P=0.032). There were no complications during or after the operation. Conclusions: Intrastromal voriconazole injection has a safe and beneficial effect on deep stromal fungal keratitis that does not respond to conventional drugs. For eyes with a wide range of lesions, the effect of pure intrastromal voriconazole injection was not good, but the cure rate can be improved when treatment is combined with conjunctival flap coverage.

Key words： fungal keratitis voriconazole corneal intrastromal injection conjunctival flap coverage

收稿日期: 2019-12-18

PACS:

基金资助:

通讯作者: 陈蔚（ORCID：0000-0001-5375-1199），Email：chenweimd@hotmail.com

引用本文:

吴思腾1 赵泽林1 潘瑜2 陈蔚1. 深基质真菌性角膜炎综合治疗方案的疗效评估[J]. 中华眼视光学与视觉科学杂志, 2020, 22(10): 750-755. Siteng Wu1,Zelin Zhao1,Yu Pan2,Wei Chen1. The Effect of a Comprehensive Treatment Regimen for Deep Stromal Fungal Keratitis. Chinese Journal of Optometry Ophthalmology and Visual science, 2020, 22(10): 750-755. DOI: 10.3760/cma.j.cn115909-20191218-00332

链接本文:

https://www.cjoovs.com/CN/ 10.3760/cma.j.cn115909-20191218-00332 或 https://www.cjoovs.com/CN/Y2020/V22/I10/750

[1]	Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol, 2004, 15(4): 321-327. DOI: 10.1097/00055735-200408000-00008.
[2]	汪斌, 胡巧娟, 李春丽. 镰刀菌属感染致眼球摘除1例. 武警后勤学院学报(医学版), 2018, 27(7): 621-622.
[3]	Kaur IP, Rana C, Singh H. Development of effective ocularpreparations of antifungal agents. J Ocul Pharmacol Ther, 2008, 24(5): 481-493. DOI: 10.1089/jop.2008.0031.
[4]	O'Day DM, Head WS, Robinson RD, et al. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res, 1986, 5(11): 877-882. DOI: 10.3109/02713688609029240.
[5]	Austin A, Lietman T, Rose-Nussbaumer J. Update on the management of infectious keratitis. Ophthalmology, 2017, 124(11): 1678-1689. DOI: 10.1016/j.ophtha.2017.05.012.
[6]	Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 2003, 41(8): 3623-3626. DOI: 10.1128/jcm.41.8.3623-3626.2003.
[7]	王倩, 罗丹, 陈华波, 等. 3 759例角膜炎患者真菌检测与耐药性分析. 中国真菌学杂志, 2019, 14(1): 16-19. DOI: 10.3969/ j.issn.1673-3827.2019.01.005.
[8]	Prakash G, Sharma N, Goel M, et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol, 2008, 146(1): 56-59. DOI: 10.1016/ j.ajo.2008.02.023.
[9]	Sharma N, Chacko J, Velpandian T, et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology, 2013, 120(4): 677-681. DOI: 10.1016/ j.ophtha.2012.09.023.
[10]	Kalaiselvi G, Narayana S, Krishnan T, et al. Intrastromal voriconazole for deep recalcitrant fungal keratitis: A case series. Br J Ophthalmol, 2015, 99(2): 195-198. DOI: 10.1136/ bjophthalmol-2014-305412.
[11]	Sharma N, Agarwal P, Sinha R, et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: Case series. Br J Ophthalmol, 2011, 95(12): 1735-1737. DOI: 10.1136/bjo.2010.192815.
[12]	Siatiri H, Daneshgar F, Siatiri N, et al. The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis. Cornea, 2011, 30(8): 872-875. DOI: 10.1097/ICO.0b013e3182100993.
[13]	程蕾, 张明昌. 真菌性角膜炎诊断常规及新进展. 临床眼科杂志, 2005, 13(5): 477-479. DOI: 10.3969/j.issn.1006-8422. 2005.05.052.
[14]	Neoh CF, Leung L, Vajpayee RB, et al. Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole. Ann Pharmacother, 2011, 45(5): e24. DOI: 10.1345/aph.1P586.
[15]	Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea, 2000, 19(3): 307-312. DOI: 10.1097/00003226- 200005000-00010.
[16]	王丽娅, 张月琴, 王印其. 中国三地区真菌性角膜病致病菌种的调查. 中华眼科杂志, 2000, (2): 138-140. DOI: 10.3760/ j:issn:0412-4081.2000.02.017.
[17]	O'Day DM. Selection of appropriate antifungal therapy. Cornea, 1987, 6(4): 238-245. DOI: 10.1097/00003226-198706040- 00002.
[18]	Gugnani HC, Talwar RS, Njoku-Obi AN, et al. Mycotic keratitis in Nigeria. A study of 21 cases. Br J Ophthalmol, 1976, 60(9): 607-613. DOI: 10.1136/bjo.60.9.607.
[19]	贺燚, 孙秉基, 赵东卿, 等. 真菌性角膜炎的临床特征及疗效观察. 中华眼科杂志, 2000, 36(5): 358-361. DOI: 10.3760/ j:issn:0412-4081.2000.05.011.
[20]	瞿玲辉, 李良毛. 真菌性角膜炎的药物治疗进展. 眼科研究, 2010, 28(2): 178-182. DOI: 10.3969/j.issn.1003-0808.2010.02. 021.
[21]	白利广. 角膜基质内注射不同药物治疗不同病原菌感染所致真菌性角膜炎. 实用医学杂志, 2018, 34(7): 1183-1187. DOI: 10.3969/j.issn.1006-5725.2018.07.033.
[22]	Niki M, Eguchi H, Hayashi Y, et al. Ineffectiveness of intrastromal v-oriconazole for filamentous fungal keratitis. Clin Ophthalmol, 2014, 8(8): 1075-1079. DOI: 10.2147/OPTH. S63516.
[23]	Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother, 2009, 53(5): 2156-2157. DOI: 10.1128/AAC.01125- 08.
[24]	Tu EY. Alternaria keratitis: Clinical presentation and resolution withtopical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea, 2009, 28(1): 116-119. DOI: 10.1097/ ICO.0b013e31818225f8.
[25]	李素霞, 史伟云, 刘明娜, 等. 结膜瓣遮盖术治疗难治性角膜溃疡. 眼科新进展, 2007, 27(3): 204-207. DOI: 10.3969/ j.issn.1003-5141.2007.03.013.
[26]	赵倩, 王婷, 史伟云, 等. 角膜移植术后复发性真菌性角膜炎的治疗及疗效分析. 中华实验眼科杂志, 2015, 33(4): 338-341. DOI: 10.3760/cma.j.issn.2095-0160.2015.04.010.
[27]	Ti SE, Scott JA, Janardhanan P, et al. Therapeutic keratoplasty for advanced suppurative keratitisl. Am J Ophthalmol, 2007, 143(5): 755-762. DOI: 10.1016/j.ajo.2007.01.015.
[28]	谢立信, 王富华, 史伟云. 1997至2002年山东省眼科研究所穿透性角膜移植术的原因分析. 中华眼科杂志, 2006, 42(8): 704-708. DOI: 10.3760/j:issn:0412-4081.2006.08.007.
[29]	Xie L, Hu J, Shi W. Treatment failure after lamellar keratoplasty for fungal keratitis. Ophthalmology, 2008, 115(1): 33-36. DOI: 10.1016/j.ophtha.2007.03.072.
[30]	王蕊. 糖尿病真菌性角膜炎患者临床特征及病原学分析. 中国真菌学杂志, 2017, 12(04): 221-224. DOI: 10.3969/ j.issn.1673-3827.2017.04.007.
[31]	黎明明, 丘亮辉, 赖江峰, 等. 糖尿病对真菌性角膜炎患者感染程度及预后的影响. 眼科新进展, 2016, 36(8): 763-766. DOI: 10.13389/j.cnki.rao.2016.0204.